Metabolomics reveals how spinach plants reprogram metabolites to cope with intense stress responses induced by photoaged polystyrene nanoplastics (PSNPs)

While land-based sources have been recognized as significant long-term sinks for micro- and nanoplastics, there is limited knowledge about the uptake, translocation, and phytotoxicity of nanoplastics (NPs) in terrestrial environments, especially aged NPs. In this study, we investigated the impact of aged polystyrene nanoplastics (PSNPs) on the uptake, physiology, and metabolism of spinach. Our findings revealed that both pristine and aged PSNPs can accumulate in the roots and subsequently translocate to the aboveground tissues, thereby influencing numerous key growth indicators in spinach plants. A more pronounced impact was observed in the treatment of aged PSNPs, triggering more significant and extensive changes in metabolite levels. Furthermore, alterations in targeted pathways, specifically aminoacyl-tRNA biosynthesis and phenylpropanoid biosynthesis, were induced by aged PSNPs, while pristine PSNPs influenced pathways related to sulfur metabolism, biosynthesis of unsaturated fatty acids, and tryptophan metabolism. Additionally, tissue-specific responses were observed at the metabolomics level in both roots and leaves. These results highlight the existence of diverse and tissue-specific metabolic responses in spinach plants exposed to pristine and aged PSNPs, providing insights into the mechanisms of defense and detoxification against NP-induced stress.

Colorectal cancer: Genetic alterations, novel biomarkers, current therapeutic strategies and clinical trials

Colorectal cancer (CRC) is the third most commonly detected cancer with a serious global health issue. The rates for incidence and mortality for CRC are alarming, especially since the prognosis is abysmal when the CRC is diagnosed at an advanced or metastatic stage. Both type of (modifiable/ non-modifiable) types of risk factors are established for CRC. Despite the advances in recent technology and sophisticated research, the survival rate is still meager due to delays in diagnosis. Therefore, there is urgently required to identify critical biomarkers aiming at early diagnosis and improving effective therapeutic strategies. Additionally, a complete understanding of the dysregulated pathways like PI3K/Akt, Notch, and Wnt associated with CRC progression and metastasis is very beneficial in designing a therapeutic regimen. This review article focused on the dysregulated signaling pathways, genetics and epigenetics alterations, and crucial biomarkers of CRC. This review also provided the list of clinical trials targeting signaling cascades and therapies involving small molecules. This review discusses up-to-date information on novel diagnostic and therapeutic strategies alongside specific clinical trials.

Riociguat for the management of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Pulmonary hypertension (PH) is a progressive disease that is accompanied by a poor prognosis. Pulmonary vasoconstriction is facilitated through multiple pathways and results in increased pulmonary vascular pressure leading to cell proliferation, vascular remodeling, right ventricular hypertrophy/failure, and ultimately death. Until recently, just six medications were approved -all for one subclass of PH. On October 8, 2013, riociguat (Adempas®) became the first medication approved for multiple etiologies of PH. Preclinical studies have demonstrated safety and efficacy with significant clinical trials supporting its advancement into phase IV trials. Although long-term safety and efficacy and place in therapy remain to be established, riociguat presents as an exciting new option for the treatment of PH and potentially has additional indications in the near future.